Abstract
Carboplatin, a member of the platinum family of alkylating agents, is often used in combination with radiotherapy. Some studies, including a recent publication from our laboratory, have suggested that the cytotoxic effects of platinum compounds may be altered by changes in the post-treatment oxygenation. The study reported here assessed whether post-treatment changes in tumor oxygenation caused by oxygen breathing alone or in combination with efaproxiral (RSR13) altered the effects of carboplatin. Efaproxiral, which allosterically modifies hemoglobin-oxygen binding to increase tumor pO(2), has been shown to increase the effects of radiation in animal tumor models and is in a second, confirmatory phase III clinical trial as an adjuvant to radiotherapy. These studies with EMT6 tumors in BALB/c Rw mice used clonogenic assays to assess tumor cell survival and tumor growth studies to assess antineoplastic activity and treatment-related toxicity. Efaproxiral plus oxygen breathing for 5 hrs after carboplatin treatment significantly increased the antineoplastic effects of carboplatin. The increased antineoplastic effects of carboplatin produced by efaproxiral plus oxygen breathing occurred without a concomitant increase in host toxicit...Continue Reading
References
Aug 1, 1979·International Journal of Radiation Oncology, Biology, Physics·E B Douple, R C Richmond
Sep 29, 1992·Biochemistry·D J AbrahamM P Kunert
Feb 1, 1991·Journal of Medicinal Chemistry·R S RandadD J Abraham
Feb 1, 1991·Journal of Medicinal Chemistry·F C WirekoD J Abraham
Dec 1, 1988·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C Grau, J Overgaard
Jan 1, 1986·Clinical & Experimental Metastasis·S RockwellM Nierenburg
Aug 1, 1984·International Journal of Radiation Oncology, Biology, Physics·S RockwellC G Irvin
May 1, 1984·International Journal of Radiation Oncology, Biology, Physics·J E Moulder, S Rockwell
Apr 1, 1980·British Journal of Cancer·I J StratfordG E Adams
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·S Rockwell
Apr 16, 1998·Journal of Applied Physiology·R S RichardsonP D Wagner
Nov 20, 1998·Radiation Oncology Investigations·S Rockwell, M Kelley
Mar 31, 1999·Journal of Neurotrauma·E M DoppenbergR Bullock
Apr 24, 2001·Protein Science : a Publication of the Protein Society·M K SafoD J Abraham
Aug 14, 2001·Radiation Research·G P AmorinoH Choy
Oct 24, 2003·Cancer Chemotherapy and Pharmacology·Erling T DonnellySara Rockwell
Dec 4, 2003·British Journal of Cancer·S KochC Bokemeyer
Mar 31, 2004·International Journal of Radiation Oncology, Biology, Physics·Erling T DonnellySara Rockwell
May 25, 2004·Expert Opinion on Investigational Drugs·John H Suh
Jun 9, 2004·International Journal of Radiation Oncology, Biology, Physics·Huagang HouHarold M Swartz
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Huagang HouHarold M Swartz